Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BY-NC-ND 4.0JACC Case Reports

Community-Based Cardio-Oncology Model for Hypertension Management in Gynecologic Oncology Patients on VEGF Inhibitors

  • Pragnya Tatikonda1
  • Lalitha C. Medepalli2
  • Christopher N. Cooper1
  • Guilherme Cantuaria3
  • Oi Wah Stephanie Yap3
  • Meaghan Tenney3
  • Jackie Wojno3
  • Christina M. Berry4
4 affiliations
  1. 1Northside Hospital Gwinnett Internal Medicine Residency Program, Lawrenceville, Georgia, USA
  2. 2Northside Hospital Heart Institute (NHHI), Northside Hospital, Atlanta, Georgia, USA
  3. 3University Gynecologic Oncology, Northside Hospital, Atlanta, Georgia, USA
  4. 4Northside Hospital Cancer Institute (NHCI), Northside Hospital, Atlanta, Georgia, USA
Read full textPDFDOICite

Abstract

Background: Vascular endothelial growth factor inhibitors (VEGFi) play an integral role in the treatment of gynecologic malignancies. However, a common limitation to treatment is hypertension, a known adverse effect of VEGFi. Patients requiring prolonged treatment with VEGFi carry a higher cardiovascular risk.

Project Rationale: There is no standardized, prospective pathway to manage VEGFi-associated hypertension and keep cancer therapy on schedule, particularly in gynecologic oncology patients with prolonged therapy and comorbidities.

Project Summary: We implemented a prospective, nonrandomized, and protocol-driven pilot quality improvement study enrolling 22 patients with gynecologic malignancies who were initiating or receiving VEGFi therapy. Management included mechanism-based antihypertensive therapy, grant-funded home blood pressure monitoring, structured education, and multidisciplinary follow-up. No patient had hypertension-related interruptions to VEGFi therapy, and most achieved control with 1 to 2 agents.

Take-Home Message: A multidisciplinary cardio-oncology pathway successfully prevented hypertension-related VEGFi treatment interruptions while emphasizing the importance of addressing broader cardiovascular comorbidities beyond hypertension alone.

Related

  1. Management Strategies for Cutaneous Adverse Events Caused by Kinase Inhibitors in Oncology: A Systematic Review and Meta-Analysis
    Renáta Árok, Fanni Adél Meznerics, Andrea Lancz +5
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  2. Perioperative inflammation in gynecologic oncology: nursing strategies for enhanced recovery and complication prevention
    Xiaoyan Chen, Zhongshu Zhang, Shanli Xie +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. From image biomarkers to treatment decisions: multimodal AI and clinical translation in gynecologic oncology
    Mohamad Bakir, Mohammad Khaldoun Al Masri, Yousef Mushtaha +3
    Frontiers in oncologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
  4. Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update
    Gregg S Nelson, Alon D. Altman, Amy Metcalfe +21
    Gynecologic OncologyPeer-reviewedCC BY-NC-NDFull text19 citedSurgery & anaesthesiaOpenAlex
  5. Psychometric properties and longitudinal measurement invariance of the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale in the Chinese colorectal cancer chemotherapy population.
    Qingchun Geng, Yang Li, Hongwen Ma +3
    Journal of patient-reported outcomesPeer-reviewedCC BYFull textOncologyEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{tatikonda2026communitybased,
  title = {{Community-Based Cardio-Oncology Model for Hypertension Management in Gynecologic Oncology Patients on VEGF Inhibitors}},
  author = {Pragnya Tatikonda and Lalitha C. Medepalli and Christopher N. Cooper and Guilherme Cantuaria and Oi Wah Stephanie Yap and Meaghan Tenney and Jackie Wojno and Christina M. Berry},
  journal = {JACC Case Reports},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jaccas.2026.109398},
  url = {https://doi.org/10.1016/j.jaccas.2026.109398},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Community-Based Cardio-Oncology Model for Hypertension Management in Gynecologic Oncology Patients on VEGF Inhibitors
AU  - Pragnya Tatikonda
AU  - Lalitha C. Medepalli
AU  - Christopher N. Cooper
AU  - Guilherme Cantuaria
AU  - Oi Wah Stephanie Yap
AU  - Meaghan Tenney
AU  - Jackie Wojno
AU  - Christina M. Berry
PY  - 2026
DA  - 2026/09/16
JO  - JACC Case Reports
DO  - 10.1016/j.jaccas.2026.109398
UR  - https://doi.org/10.1016/j.jaccas.2026.109398
AB  - Background: Vascular endothelial growth factor inhibitors (VEGFi) play an integral role in the treatment of gynecologic malignancies. However, a common limitation to treatment is hypertension, a known adverse effect of VEGFi. Patients requiring prolonged treatment with VEGFi carry a higher cardiovascular risk.  Project Rationale: There is no standardized, prospective pathway to manage VEGFi-associated hypertension and keep cancer therapy on schedule, particularly in gynecologic oncology patients with prolonged therapy and comorbidities.  Project Summary: We implemented a prospective, nonrandomized, and protocol-driven pilot quality improvement study enrolling 22 patients with gynecologic malignancies who were initiating or receiving VEGFi therapy. Management included mechanism-based antihypertensive therapy, grant-funded home blood pressure monitoring, structured education, and multidisciplinary follow-up. No patient had hypertension-related interruptions to VEGFi therapy, and most achieved control with 1 to 2 agents.  Take-Home Message: A multidisciplinary cardio-oncology pathway successfully prevented hypertension-related VEGFi treatment interruptions while emphasizing the importance of addressing broader cardiovascular comorbidities beyond hypertension alone.
SN  - 2666-0849
ER  -